Objective To evaluate the curative effect of erlotinib for advanced lung adenocarcinoma with EGFR status unknown and PS≥3. Methods 43 previously untreated patients whose EGFR status unknown and PS≥3 with advanced lung adenocarcinoma were treated from January 2010 to July 2011. 21 patients of them were treated with erlotinib( treatment group ) ,22 patients were treated with supportive treatment ( control group). Results 2 months after treatment,there were 4 patients with partial remission,8 patients with stable disease and 8 patients with progression in the treatment group, no one with complete remission. The response rate of treatment group was 19.0%, disease control rate was 57.1 %. There were 5 patients with stable disease, 16 patients with progression,and no one with complete remission or partial remission in the control group. The disease control rate of the control group was 22.7%. The differences of response rate and disease control rate between the two groups were statistically significant(P <0.01 ). The median progression-free survival of the treatment group and control group were 4.0 months and 1.0 month resepectively; the median survival time of the treatment group and control group were 7. 0 months and 3. 0 months respectively. The differences were statistically significant (P < 0. 01 ). Conclusion Erlotinib can benefit some patients with advanced lung adenocarcinoma with unknown EGFR status due to limited detection conditions, extend the survival with less adverse reaction which is tolerable to the patients.%目的 观察厄洛替尼治疗表皮生长因子受体状态未知、PS≥3分晚期肺腺癌的疗效.方法 2010年1月至2011年7月我院收治的表皮生长因子受体状态未知、PS≥3分晚期肺腺癌患者43例,治疗组21例接受厄洛替尼治疗,对照组22例仅接受支持治疗.结果 2个月后,治疗组21例中有4例部分缓解,8例稳定,8例进展,死亡1例,无完全缓解的病例;对照组22例中有5例稳定,其余16例进展,死亡1例,无完全缓解、部分缓解的病例.治疗组的客观缓解率为19.0%,疾病控制率为57.1%,对照组疾病控制率为22.7%(P<0.01);治疗组中位无进展生存期为4.0个月,中位生存期为7.0个月;对照组中位无进展生存期为1.0个月,中位生存期为3.0个月,两组比较差异有统计学意义(P<0.01).结论 厄洛替尼可使部分由于缺乏检测条件导致EGFR状态未知晚期肺腺癌患者受益,延长生存期,而不良反应少,患者可以耐受.
展开▼
